Renal Denervation Devices Market Size - Global Industry, Share, Analysis, Trends and Forecast 2023 - 2032
The Global Renal Denervation Devices Market Size accounted for USD 0.8 Billion in 2022 and is projected to achieve a market size of USD 12.7 Billion by 2032 growing at a CAGR of 28.5% from 2023 to 2032.
Renal Denervation Devices Market Highlights
- Global renal denervation devices market revenue is expected to increase by USD 12.7 Billion by 2032, with a 28.5% CAGR from 2023 to 2032
- Europe region led with more than 38% of renal denervation devices market share in 2022
- Asia-Pacific renal denervation devices market growth will record a CAGR of around 30% from 2023 to 2032
- According to the World Health Organization (WHO), hypertension affects an estimated 1.13 billion people worldwide and is responsible for approximately 9.4 million deaths each year
- By technology, the radiofrequency segment is the largest segment of the market, accounting for more than 70% of the market share in 2022
- Rising demand for minimally invasive treatment options, drives the renal denervation devices market value
Renal denervation devices are medical devices used to treat hypertension or high blood pressure. The devices use a minimally invasive procedure that delivers radiofrequency energy to the renal artery, which disrupts the overactive signaling of nerves that leads to high blood pressure. This procedure can lead to a reduction in blood pressure in patients who have been resistant to medication. Renal denervation devices have become an increasingly popular treatment option as hypertension is a widespread condition that affects a large portion of the global population.
In terms of market growth, the renal denervation devices market has shown steady growth over the past few years and is expected to continue to grow in the coming years. The increasing prevalence of hypertension, the growing geriatric population, and the rising demand for minimally invasive procedures are some of the key factors driving the market growth. However, the high cost of the procedure and lack of reimbursement policies may hinder the growth of the market to some extent.
Global Renal Denervation Devices Market Trends
Market Drivers
- Increasing global prevalence of hypertension and related health conditions
- Rising demand for minimally invasive treatment options
- Technological advancements in renal denervation devices and procedures
- Growing adoption of healthcare technology and telemedicine services
- Increasing awareness and education about hypertension and its risks
Market Restraints
- Regulatory hurdles and challenges in gaining approval for new devices and procedures
- Limited reimbursement options for renal denervation treatments
Market Opportunities
- Development of new and improved renal denervation devices and technologies
- Integration of renal denervation devices and treatments into existing healthcare systems and protocols
Renal Denervation Devices Market Report Coverage
| Market | Renal Denervation Devices Market |
| Renal Denervation Devices Market Size 2022 | USD 0.8 Billion |
| Renal Denervation Devices Market Forecast 2032 | USD 12.7 Billion |
| Renal Denervation Devices Market CAGR During 2023 - 2032 | 28.5% |
| Renal Denervation Devices Market Analysis Period | 2020 - 2032 |
| Renal Denervation Devices Market Base Year | 2022 |
| Renal Denervation Devices Market Forecast Data | 2023 - 2032 |
| Segments Covered | By Product Type, By Technology, By End User, And By Geography |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled | Medtronic, Boston Scientific Corporation, ReCor Medical, St. Jude Medical (Abbott), Cardiosonic Ltd, Kona Medical, Inc., Mercator MedSystems, Inc., Symple Surgical Inc., Vascular Dynamics, Inc., Terumo Corporation, Ablative Solutions, Inc., and Recor Medical, Inc. |
| Report Coverage |
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Covid-19 Analysis, Regulation Analysis |
Renal denervation is an endovascular catheter-based minimally invasive procedure that uses ultrasound ablation or radiofrequency ablation and aims at treating resistant hypertension. The nerves present in the renal artery are ablated by applying ultrasound pulses to the walls of renal arteries causing a reduction of sympathetic efferent and afferent activities to the kidneys and thus the blood pressure can be decreased. Earlier, the sympathectomy process was deployed for reducing hypertension but had a lot of side effects that were non-selective in nature and were poorly tolerated. Side effects included palpitations, anhydrosis, orthostatic hypotension, loss of ejaculation, intestinal disturbances, and atelectasis. Renal denervation procedure involves endovascular access through the femoral artery and often uses the catheter-mounted device in the walls of the renal artery. Generally, a number of ablations are applied at different rotational and longitudinal positions to ensure maximum denervation of nerves. Although, the process of renal denervation does not involve any permanent implant. Usually, hypertension is considered an overactive sympathetic drive and renal denervation stops the cross-talk between the brain and kidney through ultrasound and radiofrequency energy waveforms in relatively short bursts along the longitudinal path of major renal arteries to ablate the renal nerves, thus reducing the sympathetic drive.
Currently, the global renal denervation devices market is witnessing a significant surge due to an increase in the prevalence of hypertension among urban populations in various developing and developed economies including the U.S., Japan, India, China, Germany, etc. Also, changing lifestyles of people, increasing smoking and drinking habits, and increasing inclination towards adoption of preserved foods coupled with lack of physical exercises aids in increasing hypertension and high blood pressure ailments, thus driving the overall global renal treatment market. Moreover, increasing investments by governments of various economies for the improvement of healthcare infrastructure is another key factor attracting players to invest in the global renal denervation market value. Furthermore, the cost-effectiveness of the overall procedure of renal denervation is another key factor driving the overall growth of the global renal denervation systems market. However, renal denervation is a painful procedure as compared to drug-based therapies since the ultrasound waves used during the process create ablations in the renal artery thus heating the tissues. Hence, patients are less inclined towards this procedure, thus hampering the overall growth of the global renal denervation market size. Also, since renal denervation devices are highly specialized devices, the governments of various economies don’t approve of such a process which a key factor is creating hindrances to market growth. Although, increasing demand for cost-effective therapies alike renal denervation is a key factor posing bright opportunities for the global renal denervation market growth.
Renal Denervation Devices Market Segmentation
The global renal denervation devices market segmentation is based on product type, technology, end user, and geography.
Renal Denervation Devices Market By Product Type
- Simplicity Renal Denervation System
- EnligHTN
- Vessix Renal denervation System
- Iberis Renal Sympathetic Denervation System
- Paradise Renal Denervation System
- Others
According to the renal denervation devices industry analysis, the simplicity segment accounted for the largest market share in 2022. The simplicity segment refers to devices that use the Symplicity technology, which was developed by Medtronic, Inc. and was the first renal denervation technology to gain approval from regulatory agencies. Symplicity devices use radiofrequency energy to ablate the renal nerves, thereby reducing blood pressure levels in patients with hypertension. The simplicity segment of the market has seen significant growth in recent years, driven by factors such as the rising global prevalence of hypertension and the increasing adoption of minimally invasive treatment options.
Renal Denervation Devices Market By Technology
- Radiofrequency
- Ultrasound
- Micro-Infusion
In terms of technology, the radiofrequency segment is expected to witness significant growth in the coming years. The radiofrequency segment of the renal denervation devices market refers to devices that use radiofrequency energy to ablate the renal nerves and reduce blood pressure levels in patients with hypertension. This segment includes devices such as Symplicity, EnligHTN, V2, and others. Radiofrequency renal denervation devices are typically minimally invasive and can be performed in a relatively short amount of time. The radiofrequency segment of the market has seen significant growth in recent years, driven by factors such as the rising global prevalence of hypertension, increasing demand for minimally invasive treatment options, and advancements in renal denervation technology. One of the key advantages of radiofrequency renal denervation devices is their ability to selectively target and ablate the renal nerves while sparing surrounding tissues and organs. This can lead to improved patient outcomes and reduced risk of complications.
Renal Denervation Devices Market By End User
- Hospitals
- Specialty Clinics
- Others
According to the renal denervation devices market forecast, the hospital segment is expected to witness significant growth in the coming years. This growth is driven by factors such as the increasing global prevalence of hypertension and the growing adoption of minimally invasive treatment options. One of the key advantages of the hospital segment is its ability to provide comprehensive care to patients with hypertension, including diagnosis, treatment, and follow-up care. Hospitals and healthcare facilities can also provide patients with access to a wide range of resources and support services, such as patient education programs and counseling services.
Renal Denervation Devices Market Regional Outlook
North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- India
- Japan
- China
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
The Middle East & Africa
- South Africa
- GCC Countries
- Rest of the Middle East & Africa (ME&A)
Renal Denervation Devices Market Regional Analysis
Europe is currently the dominant market for renal denervation devices, accounting for a significant share of the global market. This is due to several factors, including the high prevalence of hypertension and related health conditions in the region, as well as favorable reimbursement policies and regulatory frameworks that support the adoption of new medical technologies. One key driver of the renal denervation devices market in Europe is the growing awareness and understanding of hypertension as a major health concern. Governments and healthcare organizations in Europe have made significant efforts to educate the public about the risks and consequences of hypertension, leading to increased demand for effective and minimally invasive treatment options. In addition, the European regulatory environment has been favorable to the development and commercialization of renal denervation devices, with several companies gaining approval from regulatory agencies such as the European Medicines Agency (EMA) to market their products in the region.
Renal Denervation Devices Market Player
Some of the top renal denervation devices market companies offered in the professional report include Medtronic, Boston Scientific Corporation, ReCor Medical, St. Jude Medical (Abbott), Cardiosonic Ltd, Kona Medical, Inc., Mercator MedSystems, Inc., Symple Surgical Inc., Vascular Dynamics, Inc., Terumo Corporation, Ablative Solutions, Inc., and Recor Medical, Inc.
Frequently Asked Questions
What was the market size of the global renal denervation devices in 2022?
The market size of renal denervation devices was USD 0.8 Billion in 2022.
What is the CAGR of the global renal denervation devices market from 2023 to 2032?
The CAGR of renal denervation devices is 28.5% during the analysis period of 2023 to 2032.
Which are the key players in the renal denervation devices market?
The key players operating in the global market are including Medtronic, Boston Scientific Corporation, ReCor Medical, St. Jude Medical (Abbott), Cardiosonic Ltd, Kona Medical, Inc., Mercator MedSystems, Inc., Symple Surgical Inc., Vascular Dynamics, Inc., Terumo Corporation, Ablative Solutions, Inc., and Recor Medical, Inc.
Which region dominated the global renal denervation devices market share?
Europe held the dominating position in renal denervation devices industry during the analysis period of 2023 to 2032.
Which region registered fastest CAGR from 2023 to 2032?
Asia-Pacific region exhibited fastest growing CAGR for market of renal denervation devices during the analysis period of 2023 to 2032.
What are the current trends and dynamics in the global renal denervation devices industry?
The current trends and dynamics in the renal denervation devices industry include increasing global prevalence of hypertension and related health conditions, rising demand for minimally invasive treatment options, and technological advancements in renal denervation devices and procedures.
Which technology held the maximum share in 2022?
The radiofrequency technology held the maximum share of the renal denervation devices industry.
Select Licence Type
Connect with our sales team
Why Acumen Research And Consulting
100%
Customer Satisfaction
24x7
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
